Exogenous osteoprotegerin (OPG) gene modification appears a therapeutic strategy for osteolytic aseptic loosening. The feasibility and efficacy of a cell-based OPG gene delivery approach were investigated using a murine model of knee prosthesis failure. A titanium pin was implanted into mouse proximal tibia to mimic a weightbearing knee arthroplasty, followed by titanium particles challenge to induce periprosthetic osteolysis. Mouse fibroblast-like synoviocytes were transduced in vitro with either AAV-OPG or AAV-LacZ before transfused into the osteolytic prosthetic joint 3 weeks post surgery. Successful transgene expression at the local site was confirmed 4 weeks later after killing. Biomechanical pullout test indicated a significant restoration of implant stability after the cell-based OPG gene therapy. Histology revealed that inflammatory pseudomembranes existed ubiquitously at bone-implant interface in control groups, whereas only observed sporadically in OPG gene-modified groups. Tartrate-resistant acid phosphatase+ osteoclasts and tumor necrosis factor a, interleukin-1b, CD68+ expressing cells were significantly reduced in periprosthetic tissues of OPG gene-modified mice. No transgene dissemination or tumorigenesis was detected in remote organs and tissues. Data suggest that cell-based ex vivo OPG gene therapy was comparable in efficacy with in vivo local gene transfer technique to deliver functional therapeutic OPG activities, effectively halted the debrisinduced osteolysis and regained the implant stability in this model.
Introduction
Total joint replacement is a highly successful procedure for the treatment of severe destructive arthritis. Although failures of the surgery because of infections and errors have been greatly reduced in recent years, aseptic prosthetic loosening remains the most common complication of total joint replacement and represents a major problem for the long-term success and survival of prostheses. 1 Wear debris-induced inflammation and osteoclastic resorption at the bone-implant interface are believed to have critical roles in the pathogenesis of aseptic loosening. 2 It has been accepted that particles generated during the mechanical wear of prosthetic components are phagocytosed by macrophages and other inflammatory cells, resulting in cellular activation and release of pro-inflammatory mediators and cytokines such as interleukin-1 (IL-1b), tumor necrosis factor (TNFa), and IL-6. 3 These cytokines in turn provoke cellular proliferation, promote osteoclastogenesis, and stimulate mature osteoclasts to absorb the adjacent bone. 4, 5 This process impacts bone remodeling around the implant and leads to osteolysis and aseptic loosening. 6 The receptor activator of nuclear factor NF-kB ligand (RANKL)/osteoprotegerin (OPG) pathway has a key role in bone metabolism and osteolysis. RANKL is mainly expressed by macrophages, osteoblasts, marrow stromal cells, and lymphocytes. RANKL binds to RANK, a receptor on the cell surface of osteoclasts and osteoclast precursors, resulting in proliferation, differentiation, and maturation of osteoclasts, which can subsequently promote local osteolysis. 7 In contrast, OPG, a secreted protein with homology to members of the TNF superfamily, is considered to be a natural decoy receptor that profoundly modifies the effects of RANKL by inhibiting RANKL/RANK interaction. 8, 9 Mice genetically deficient for RANKL or RANK suffered severe osteopetrosis, 10, 11 and OPG transgenic mice share the same pathology, 12 showing that RANKL and RANK are essential for osteoclast development and OPG is a potent negative regulator for osteoclastogenesis.
On the basis of the anti-osteolytic nature of OPG, it appears to be a potential therapeutic agent to treat debris-associated periprosthetic bone resorption and aseptic loosening. However, the delivery of OPG to chronic periprosthetic osteolytic sites remains problematic. Current systemic anti-inflammation or antiosteolysis therapies have several weaknesses including high-dose requirements with modest efficiency, systemic side effects, and the tendency for poor patient compliance. 13 Gene therapy, though still in its infancy, provides an attractive alternative to treat aseptic loosening as the transfer of genes may facilitate the continuous release of therapeutic proteins. Using a mouse calvaria model, Goater et al. 14 were the first to examine the potential of ex vivo OPG gene therapy with stably transfected fibroblast-like synoviocytes (FLS) expressing OPG in preventing wear debris-induced osteoclastogenesis. We recently reported that in vivo gene transfer of OPG effectively blocked osteoclastogenesis and reversed periprosthetic bone resorption using a newly characterized mouse model of knee prosthesis failure. 15 This study extended the investigation to evaluate the therapeutic effects of a cell-based OPG gene modification by delivering the stable OPG-transduced FLS into the failing knee prosthesis, in comparison with the direct in vivo gene transfer approach. The biomechanical properties of failing knee pin implantation after gene modification were also assessed.
Results

OPG and LacZ gene transduction efficacy in FLS
In preparation for the ex vivo gene therapy experiments, target cells stably expressing OPG and b-galactosidase (LacZ) were engineered by infecting the primary FLS with AAV-OPG-EGFP or AAV-LacZ, respectively. Fluorescent microscopy identified green fluorescent signals on cells transduced with AAV-OPG-EGFP. X-gal stain was used to trace LacZ gene-transduced cells. The transduction efficiencies in the FLS for both vectors were higher than 90% at day 3 and were maintained for at least 4 weeks (Figures 1a, b , and c).
Outcome of surgical procedures
A custom-made titanium pin was implanted into mouse proximal tibia to form a weight-bearing knee implant. The mice tolerated surgery well and ambulated with the implanted limbs within 3 days after surgery. Injections of titanium particles and FLS into the prosthetic knees appeared to exert no influence on their daily activity. The macroscopic examination of the prosthetic joints at killing revealed that the metal pins positioned in proximal tibiae with no signs of scratching or inflammation on opposing articulate surfaces. There were no obvious surgical differences between the groups to the naked eye, except that a few pin implants from non-treated or LacZ-treated groups could be rotated or moved by hand because of loss of the fixation.
Transgene expression and dissemination
RNA extracted from the treated joints and other organs/ tissues from animals with ex vivo OPG gene therapy were examined by conventional reverse transcription-polymerase chain reaction (RT-PCR) with human OPG primers. No positive PCR products were detected, except for the periprosthetic tissues where the ex vivo gene transfer was conducted (Figure 1e) , where results were similar to in vivo OPG treatment. 15 All prosthetic joint samples with ex vivo LacZ gene transfer exhibited dark blue coloration (Figure 1d ). ELISA confirmed that OPG protein production in FLS-AAV-OPG culture medium was 4.20 ng per 72 h per 10 6 cells, where OPG levels in periprosthetic tissues from ex vivo OPG-treated groups were 2.60 ng mg À1 total protein at killing, comparable with levels observed during in vivo OPG treatment. The implanted pin pullout test was performed to examine the mechanical stability of the implant after wear debris challenge and gene therapy. The average peak interfacial shear strength against pulling was 10.34 ± 2.05, 8.14 ± 1.23, and 7.32 ± 1.35 N in AAV-LacZ, FLS-AAV-LacZ, and virus-free non-treated groups, respectively. There was no statistical difference between the three groups. However, the ex vivo and in vivo OPG gene therapies significantly increased the implant stability. The pulling forces of 21.56±2.44 and 18.19 ± 2.10 N were required to dissociate the pin implants from tibiae, respectively ( Figure 2 ). There was no statistical difference between the two OPG genemodified groups.
Histological analysis
Histological evaluation on cross-sections of prosthetic tibiae revealed ubiquitous presence of inflammatory fibrous membranes at the bone-implant interface in both FLS-AAV-LacZ and non-treated control groups. However, the interface membranes in sections from the FLS-AAV-OPG group were dramatically thinner, and even resolved in many of the samples. Figure 3 illustrates a typical micrograph of peri-implant pseudomembranes among the groups, and Figure 3f summarizes the measurements of membrane thickness, indicating that both in vivo and ex vivo OPG gene transfer significantly blocked the periprosthetic membrane formation. There was no significant difference between the two OPG-treated groups with respect to interfacial membrane thickness ( Figure 3 ). Modified trichrome staining was performed to reveal changes in bone collagen content. 16 Although the periprosthetic bone tissues from AAV-LacZ, FLS-AAVLacZ and virus-free groups generally exhibited weak staining of trichrome blue coloration, OPG gene modification using in vivo or ex vivo delivery markedly enhanced the staining as seen previously. 17 Quantified intensity analysis by computerized image analysis system confirmed the statistical significance (Po0.01, Figure 4 ).
Immunohistochemistry analysis and tartrate-resistant acid phosphatase staining
A profound accumulation of CD68+ macrophages, and TNFa and IL-1 expressing cells were observed at the interface between the pin and surrounding bone in sections from both FLS-AAV-LacZ and virus-free nontreated groups. In contrast, significantly less positive cells were present on tissue sections from OPG genemodified groups ( Figure 5 ). There was also a marked reduction of tartrate-resistant acid phosphatase (TRAP)+cells in the sections from OPG gene-modified animals in comparison with LacZ-treated and virus-free groups (Po0.01, Figure 4 ).
Discussion
Despite successful outcomes of total joint replacement surgery, aseptic prosthetic loosening remains the single most common long-term complication. Implant wear is widely recognized as the major initiating event in the development of periprosthetic osteolysis and aseptic loosening. 18 Evidence includes observations that osteolysis was correlated with higher wear rates 19 and vast numbers of wear particles were found in periprosthetic interfacial membranes removed during revision surgery. 20, 21 Studies indicate that wear debris particles may promote periprosthetic inflammation and subsequent bone resorption to lead to the prosthesis failure. 17, 22 Osteoclasts, derived from hematopoietic precursors of the monocyte/macrophage lineage, are multinucleated giant cells that specialize in resorbing bone. Osteoclast precursors interact with osteoblasts and stromal cells to differentiate into mature osteoclasts. 23 RANKL is a cytokine-like protein expressed by osteoblasts, stromal cells, and some lymphocytes 24 that appears central to the promotion of osteoclast maturation and activity through its binding to RANK, the physiological receptor located on surface of osteoclasts and their progenitor cells. OPG is a soluble protein that may competitively bind to RANKL to negatively regulate the interaction between RANKL and RANK. It is the balance between the expression of the stimulator of osteoclastogenesis, RANKL, and the inhibitor, OPG that dictates the quantity of bone resorption and remodeling. 25 Thus, OPG may be an effective therapeutic candidate to retard the process of debris-associated inflammatory osteolysis and aseptic loosening of the prosthetic joint. The delivery of the potential therapeutic agent (OPG) to the chronic periprosthetic osteolytic site remains problematic. Although conventional systemic administration of biological drugs relies on vascular perfusion to the local sites of loosening (requiring relatively high doses and repeated administrations), the delivery of therapeutic genes to sites of disease appears appropriate to achieve the expression of therapeutic proteins in a persistent and localized manner. We and others have evaluated in vivo gene therapy for aseptic loosening by directly injecting viral vectors encoding therapeutic protein and/or markers using various models. [15] [16] [17] 22, 26 However, concerns remain over the safety of these approaches because of the lack of control over the phenotype of infected cells and the level of incorporated transgene. Potential side effects of in vivo administration include adverse immunological reactions, vector-mediated cytotoxicity, vector-mediated transgene Figure 2 Summary of maximum pulling force required to pull out the implants at 4 weeks after treatments (*Po0.05). The inset illustrates an example trace of pulling forces applied to extract the pin implant from the surrounding bone.
OPG cell therapy for aseptic loosening L Zhang et al dissemination, and oncogenesis. Ex vivo strategies using cell-based gene delivery may circumvent some of these obstacles. Using fibroblast-like synovial cells from homologous donor mice, the stable OPG gene was successfully transduced in vitro, in agreement with the results elsewhere. 14 When the gene-modified FLS were returned to the joint tissues, they localized in knee joint periprosthetic tissue and expressed the target protein. Therefore, we have showed the feasibility of ex vivo gene transfer technique and the cell-based OPG therapy on the mouse model of titanium particle-induced knee prosthesis loosening.
In vitro gene modification of fibroblast-like synovial cells resulted in elevated and persistent OPG protein in FLS culture medium 3 days after viral infection. After the cell transfer to the prosthetic joint, OPG levels appeared comparable to in vivo OPG-treated mice. The data indicate that the exogenous OPG gene was stably The ex vivo OPG gene therapy resulted in a successful therapeutic influence by reversing inflammatory bone resorption, increasing new bone formation, preserving bone collagen content, and blocking osteoclast infiltration and maturation, with the significant reduction in TRAP-positive cells after OPG-modified FLS transfusion supporting this observation. We consistently found that overexpression of OPG also decreased the accumulation of TNFa and IL-1 expressing cells at the interface between the pin and surrounding bone in both OPG gene-treated groups. 15 CD68+ macrophages in the periprosthetic membrane were also reduced compared with other control groups. The mechanism of this antiinflammation phenomenon is currently unclear. Although there is no evidence that OPG directly influences local inflammatory cascades, reversion of debris-induced periprosthetic osteolysis and reduction of micromotion of prosthetic implant component as the results of RANK/OPG rebalance may subsequently ameliorate and prevent micromotion-induced local inflammation and periprosthetic pseudo-membrane formation.
Implant stability is the major determinant of interfacial strength, and testing the interfacial strength by pullout tests represents a useful means to evaluate implant stability. Chang et al. 27 used pullout test to measure peak load duration in a similar study of bone-implant interface showing that the interfacial shear load values, peak, and its duration were influenced by the bone bonding and could be indications for implant stability. Using a custom jig and dental cementing techniques, we have successfully developed a pullout test for the mouse pinimplantation model. Both the in vivo and ex vivo OPG gene therapies dramatically restored the implant stability, to the comparable level of the non-particlechallenged stable implantation. In spite of the small size of mouse tibiae and the custom pin implants, the biomechanical pullout data were consistent and reproducible.
One limitation of this study is that only one time point (28 days post surgery) was evaluated for the efficacy and safety of the cell-based gene therapy. Dynamic and longterm studies are warranted to evaluate the therapeutic influence, the fate of the engineered cells, and the potential side effects.
However, this study suggests that ex vivo gene modification inhibited Ti particle-induced local osteolysis by blockage of osteoclastogenesis and alteration of inflammatory cell infiltration. There was no significant difference at this evaluation time point between the ex vivo and in vivo therapeutic approaches. Overall, the murine model of the knee prosthesis appears an excellent tool to evaluate therapeutic approaches to debrisassociated joint prosthesis failure at biomechanical, histological, biochemical, and molecular levels.
Materials and methods
Establishment of the mouse model of knee pin implantation
The Institutional Animal Care and Use Committee (IACUC, Wichita State University, KS, USA) approved all the animal surgery and care procedures. The mouse model was established as described earlier. 13 Sixty BALB/c mice aged 10-12 weeks were obtained from Jackson Laboratories (Bar Harbor, ME, USA) and quarantined in our animal facility for 2 weeks before experimentation. All mice weighed at least 20 g at surgery. Mice were anesthetized by i.p. injection of a mixture of xylazine at 10 mg kg À1 and ketamine at 120 mg kg À1 . The left hind limb area was shaved using an electric animal clipper and scrubbed with proividine followed by a rinse of 70% alcohol. A 5 mm medial parapatellar incision was made to expose patellar Figure 5 Immunohistochemical-stained periprosthetic tissue sections to detect mouse IL-1b (upper panels), TNFa (middle panels), and CD68 (lower panels).
OPG cell therapy for aseptic loosening L Zhang et al ligament. The patella was dislocated laterally to expose the tibial plateau. The cartilage of the tibial plateau was partially removed by a #11 scalpel. The center of the tibial plateau was reamed to form a circular indent of 1.2 mm diameter and 0.3 mm depth. The proximal 5 mm of the tibial intramedullary canal was reamed with a 0.7 mm dental drill through the center of the plateau. A custommade titanium-alloy pin of 0.8 mm in diameter and 5 mm in length with a round flat top of 1.2 mm diameter (the generous gift of Stryker Orthopaedics, Mahwah, NJ, USA) was press-fit inserted into the canal in a manner that the surface of the pin head was flush with the cartilaginous surface of the tibial plateau. To mimic wear debris-associated prosthesis failure, 20 ml of titanium particle suspension was injected into the tibia canal before insertion of the pin. The wound was cleaned and rinsed with PBS containing penicillin G (500 unit per ml) and streptomycin (500 mg ml À1 ), before closure of the layers using sutures.
The titanium particles (50 mg ml À1 Ti-6Al-4V) used in this experiment were kindly provided by Zimmer Inc. (Warsaw, IN, USA) and the size of the particles (mean particle size 2.3 um with a range of 0.1-68 mm) was similar to debris retrieved from periprosthetic tissues of patients revised for aseptic loosening. 15 To mice in all groups, 50 ml of debris particles was intra-articularly injected into the prosthetic joint again 4 weeks later.
Viral vectors and in vivo gene transfer
The recombinant adeno-associated virus coding for OPG was constructed using multiple sub-cloning steps as detailed earlier, 17 and packaged by Gene Core Facility, University of North Carolina (UNC) at Chapel Hill, NC, who prepared the purified rAAV-OPG-IRES-EGFP using type 2 rAAV. The rAAV-LacZ control vectors were obtained from the Gene Core Facility, UNC. For in vivo gene transfer groups, 50 ml of rAAV-OPG-EGFP or AAVLacZ at titers of 10 7 p.f.u. were injected, respectively, into the prosthesis joints at 3 weeks post pin-implantation surgery when Ti particle induced periprosthetic osteolysis and pseuo-domembrane formation was established. 13 Mouse FLS isolation and cell-based gene transfer FLS were isolated from the knees of adult BALB/c mice as described elsewhere. 28 After careful removal of the skin and muscles, the tissue of the knee joint was minced, digested with 1 mg ml À1 of collagenase (Sigma, St Louis, MO, USA) in serum-free RPMI 1640 (Life Technologies, Rockville, MD, USA) for 2 h at 37 1C, filtered through nylon mesh, and washed extensively. Cells were cultured in DMEM supplemented with 10% FBS and 1% penicillin/streptomycin in a humidified 5% CO 2 atmosphere. After overnight culture, non-adherent cells were discarded and adherent cells were cultured in DMEM-10% FBS. The cells were sub-cultured at 1:5 ratios when the cultures reached confluence, and FLS at passages 2 or 3 were used for gene transduction when confluence of 30-40% was achieved. Cells were co-cultured with 10 7 particles per milliliter titer of AAV-OPG-EGFP and AAVLacZ, and a second dose of viral vectors at titer of 10 7 was added into culture 6 h later. Transduction efficacy was determined by fluorescent microscopy (for the emission of GFP) and X-gal staining (for LacZ transduction) as described earlier. 17 Stable transduced FLS were injected into the implanted joints of mice at 3 weeks post operation.
Experimental course
The mice were divided into five groups: (1) in vivo AAV-OPG group given an intra-articular injection of AAV-OPG-EGFP at titer of 10 6 in 50 ml medium (n ¼ 12); (2) ex vivo FLS-AAV-OPG group given an intra-articular injection of 50 ml medium containing 10 6 of OPGengineered FLS cells (n ¼ 12); (3) in vivo AAV-LacZ group given an intra-articular injection of AAV-LacZ at titer of 10 6 in 50 ml medium (n ¼ 12); (4) 10 6 LacZ-transduced FLS cells in 50 ml medium was intra-articularly injected into the implanted joints of FLS-AAV-LacZ control mice (n ¼ 12); (5) 12 non-treated control mice received an intraarticular injection of 50 ml virus-free medium.
Mice were killed at 4 weeks after gene therapy. Ten implanted knee joints from each group were collected for pullout testing and histological evaluation, whereas the other two implanted joints, along with the lungs, liver, spleen, kidneys, muscles from contralateral limb, and lymph nodes of subiliac and axillary regions were snapfrozen and stored for transgene detection.
Interfacial shear strength test
The limb with the implanted titanium pin was removed by disarticulating from knee joint after killing. All soft tissue around the prosthetic joint was carefully removed to expose the implanted pin surface and proximal tibia. Approximately 10 mm of the distal tibia was cemented into a custom-designed jig using dental cement (Garreco; Herber Springs, AR, USA). Proper alignment was achieved by positioning the tibia titanium implant vertically for pullout testing. The dental cement was allowed to cure for a minimum of 30 min before testing. Another custom fixture was designed to align the long axis of the orthopedic implant with the loading axis of the MTS 858 Bionix material testing system (MTS Model 858; Eden Prairie, MN, USA) ( Figure 6 ). After the fixture was attached to the loading cell, the MTS 858 actuator pulled the implant out of the bone at a rate of 2.0 mm min À1 under displacement control. Actuator positions and loading data were recorded. 
Histological and immunohistochemical analysis
After the pullout test, the peri-implant proximal tibiae were formalin fixed and decalcified using formic acid/sodium citrate solution before paraffin embedding and mounting with either cross or longitudinal orientation for cutting 6 mm sections. Sections were stained with hematoxylin and eosin to examine new bone formation or bone erosion around the prosthetic pin, and the evidence of debris-associated inflammation (periprosthetic tissue formation and cellular infiltration). The thickness of the periprosthetic membrane was measured using Image-Pro+ software (Media Cybernetics, Silver Spring, MD, USA).
Modified trichrome staining was performed to examine bone collagen changes. 17 Briefly, sections were deparaffinized and hydrated before equilibrating in Bouin's solution (70% picric acid, 5% glacial acetic acid, and 10% formaldehyde) at 56 1C for 1 h. The sections were incubated in phosphomolybdic (0.21% w/v)-phosphotungstic acid (0.21% w/v) for 10 min, followed by aniline blue solution (2.5% aniline blue in 2% acetic acid) stain for 5 min, and then incubated in 1% acetic acid for 4 min before dehydration in graded alcohol. The bone collagen acquired a blue stain, with the stain density proportionate to the collagen content. 17 Immunohistochemical was performed to reveal IL-1b, TNFa, and CD68 expressions in peri-implant tissues. 29 Briefly, tissue sections were deparaffinized, re-hydrated, and microwaved before blocking with 1.5% normal goat serum for 1 h. The sections were incubated with primary antibodies anti-mouse TNFa (Abcam, Cambridge, MA, USA), IL-1b, or CD68 (Santa Cruz, Santa Cruz, CA, USA) (diluted in 1.5% normal goat serum per 50 mM Tris buffer, PH7.6) overnight in a moisturized chamber at 4 1C. Biotin-conjugated secondary antibody (goat antirabbit IgG) was followed for 30 min after 3 Â washes. Avidin-biotin enzyme reagent was applied onto sections for 30 min. The color was developed by adding 3.3 0 -diaminobezidine tetrahydrochloride or alkaline phosphatase. In negative control sections, the primary antibody was replaced by non-immune rabbit sera at the same concentration as the primary antibody. Digital images of immunohistochemical-stained sections and modified trichrome-stained sections were captured. The levels of the positive stains and localizations were evaluated in four random fields per section and expressed as integrated optical density, using the Image-Pro Plus software. 17 
TRAP stain for osteoclasts
A commercial kit (Sigma-Aldrich, St Louis, MO, USA) was used for histological TRAP staining on paraffinsectioned prosthetic joints after pin removal. After deparaffinization and rehydration, the sections were permeated in a microwave oven for 30 s before brief fixation in buffered acetone. The sections were then incubated at 37 1C for 1 h in 0.1 M acetate buffer (pH 5.2), containing 0.5 mM naphthol AS-BI phosphoric acid, 2.2 mM Fast Garnet GBC, and 10 mM sodium tartrate. The reaction was stopped by washing in several changes of distilled water. TRAP+ cells in the periprosthetic membrane were detected by the presence of dark purple staining granules in the cytoplasm.
Transgene expression assessment
Conventional RT-PCR was performed to detect OPG gene expression at the local delivery site and the remote organs/tissues. Hard and soft tissues were minced on dry ice followed by polytron homogenization (PT-MR2100; Kinematica, Lucerne, Switzerland). Total RNA was extracted with trizol reagent (Invitrogen, Carlsbad, CA, USA) in accordance with the manufacturer's protocol. Extracted total RNA was treated with deoxyribonuclease I to eliminate genomic DNA according to the vendor's instructions. One microgram of total RNA, after DNase treatment, was reverse transcribed to cDNA in a Perkin-Elmer Thermal cycler (PerkinElmer, Branford, CT, USA). 17 The detection of OPG transgene was performed by conventional PCR using 2 ml of cDNA template, 0.4 mM of forward and backward primers, 2.5 U Taq DNA polymerase, 0.2 mM dNTPs, and 1.5 mM MgCl 2 . The PCR was run for 35 cycles with denaturing at 94 1C for 1 min, annealing at 60 1C for 55 s, and elongation at 72 1C for 60 s. The PCR product was electrophoresed on 1.5% agarose gels to confirm the amplification of OPG gene. The transgene product, human OPG protein levels in FLS-AAV-OPG culture medium, and variant prosthetic joint tissue were determined by a quantitative sandwich enzyme immunoassay technique (ELISA) using capture and detection monoclonal antibody pairs against different epitopes of OPG (R&D systems, Minneapolis, MN, USA), and the standardized protocol was detailed earlier.
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Statistical analysis
Data from three independent experiments were analyzed for this study. A total of 60 animals were investigated and were distributed at 12 animals for each group. Statistical analysis among groups was performed by oneway ANOVA test with the Schafer formula for post hoc multiple comparisons (SPSS v10, Chicago, IL, USA). A P-value of o0.05 was considered as significant difference. Data are expressed as mean ± standard errors of the mean.
